Listed by the USPTO as WELLS, LAUREN QUINLAN
Tech Center 1600 • Art Units: 1622 1625 1626 1629
This examiner grants 49% of resolved cases
WELLS, LAUREN QUINLAN is assigned to Tech Center 1600 and Art Unit 1622. The profile records 261 resolved cases, a 49.4% allowance rate, and a median of 1120 days to allowance. The 59.5% interview lift indicates that interviews were associated with a substantial improvement over the stated baseline.
Bristol-Myers Squibb Company, INCYTE Corporation, and Genentech Inc. are the leading companies. The leading firms are BALLARD SPAHR LLP, FENWICK & WEST LLP, and FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER. The mixed allowance result and strong interview signal support building direct examiner engagement into prosecution planning, while maintaining detailed written support for claim amendments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18859397 | SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE | Non-Final OA | Genentech, Inc. |
| 18835859 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18032320 | USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN | Final Rejection | Compass Pathfinder Limited |
| 18003431 | HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY | Final Rejection | The Regents of the University of Michigan |
| 18875584 | PRODRUGS OF PAN-KRAS INHIBITORS | Non-Final OA | Mirati Therapeutics, Inc. |
| 17904393 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | Non-Final OA | UCL BUSINESS PLC |
| 18720716 | COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18697655 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | Final Rejection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18903075 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Non-Final OA | Vanderbilt University |
| 18706095 | USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 18630042 | ACCESSING AND MODULATING THE COLOR AND VIBRANCY OF ANODICALLY COLORING ELECTROCHROMIC MOLECULES | Final Rejection | Georgia Tech Research Corporation |
| 18724765 | COLLAGEN CROSS-LINKER AND USES THEREOF | Non-Final OA | The Curators of the University of Missouri |
| 18109406 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18834032 | METHOD FOR INACTIVATING VIRUSES OR BACTERIA | Non-Final OA | Kao Corporation |
| 18718477 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18026704 | DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES | Final Rejection | Bristol-Myers Squibb Company |
| 17928894 | THERAPEUTIC DRUG FOR DISEASE CAUSED BY INTESTINAL IMMUNE DISORDER | Non-Final OA | KEIO UNIVERSITY |
| 19062656 | SOLID FORMS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, AND OXALIC ACID, COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | BeiGene Switzerland GmbH |
| 18973200 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | Non-Final OA | INCYTE CORPORATION |
| 18500214 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | Final Rejection | INCYTE CORPORATION |
| 18879103 | INSECTICIDE FORMULATIONS WITH BUILT-IN ADJUVANTS | Non-Final OA | ADAMA MAKHTESHIM LTD. |
| 18746787 | NANOMATERIALS COMPRISING DISULFIDES | Non-Final OA | Beam Therapeutics Inc. |
| 18762266 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | Non-Final OA | Crinetics Pharmaceuticals, Inc. |
| 17798667 | METHOD OF DECREASING AMYLOID BETA MONOMER LEVELS IN PATIENTS WITH COGNITIVE DECLINE | Non-Final OA | Cognition Therapeutics, Inc. |
| 18088131 | TOPICAL WORKOUT MUSCLE RECOVERY COMPOSITION AND ITS METHOD OF APPLICATION | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy49.4% of resolved applications examined by Lauren Quinlan Wells were allowed (261 resolved cases), compared with 60.5% across Art Unit 1622 over the last five years.
This examiner's interview lift is +59.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Lauren Quinlan Wells took 1,120 days on average from filing to allowance.
Lauren Quinlan Wells examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).